ArticleInfection and drug resistance2025
Comparative Efficacy of High-Dose Daptomycin Monotherapy versus Combination Therapy for Daptomycin-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Outcomes and Adverse Events Among Patients with Vancomycin-Resistant Enterococcal Bloodstream Infection Treated with Daptomycin Doses Greater than 12 mg/kg.Infectious diseases and therapy · 2026Article
- Enhanced miR-214 in Vascular Endothelial Cells Retards Renal Inflammation and Glomerular Sclerosis in Five-Sixths Nephrectomy Mice.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infections caused by daptomycin-resistant and vancomycin-resistant Methods: A clinical DRE isolate (daptomycin MIC, 8 mg/L) was used to establish IE in Wistar rats. After 48 h, the animals were randomized to three-day regimens: saline control, daptomycin 90 mg/kg/day s.c. (D90), daptomycin 125 mg/kg/day s.c. (D125), D90 plus fosfomycin 500 mg/kg/day i.p. (D90F), or D90 plus ceftaroline 40 mg/kg q8 h i.m. (D90C). Efficacy was evaluated by quantifying colony-forming units (CFU) in excised cardiac vegetation. Results: A strong correlation was observed between higher daptomycin exposure (Cmax/MIC and AUC Conclusion: In this severe DRE infection model, escalating the daptomycin dose was more effective in clearing bacteria from the cardiac vegetation than combining a standard high dose with a synergistic agent. These findings suggest that higher daptomycin exposure may be a viable strategy for managing DRE infections, pending clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.